AVRO 1.4 (-91.67%)
US05455M1009BiotechnologyBiotechnology

Avrobio (AVRO) Stock Highlights

1.4 | -91.67%
2024-06-22 04:43:40
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The companys pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Statistics

Range Today
1.4 1.4
Volume Today 0
Range 1 Year
0.88 18.48
Volume 1 Year 116.07M
Range 3 Year
0.56 18.48
Volume 3 Year 508.79M
Range 10 Year
0.56 53.7
Volume 10 Year 728.78M

Highlights

Market Capitalization 5.24M (micro)
Floating Shares 2.57M
Current Price 1.4
Price To Earnings 0.17
Price To Book 0.06
Earnings Per Share 8.28
Payout Ratio 0%

Performance

Latest -91.67%
1 Month -91.67%
3 Months +11.11%
6 Months +5.26%
1 Year +30.84%
3 Years -85.19%
5 Years -90.34%
10 Years -95.25%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.